Abstract:[Abstract] Objective To evaluate the clinical effect of Nimotuzumab combined with Cisplatin concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods According to different treating methods, 66 cases of patients with advanced nasopharyngeal carcinoma treated in the First Affiliated Hospital of Xi'an Jiaotong University from January 2011 to January 2013 were assigned into two groups. 33 cases in the control group received Cisplatin concurrent chemoradiotherapy treatment, while 33 cases in the observation group received Nimotuzumab combined with Cisplatin concurrent chemoradiotherapy. The efficacy of the two groups was compared. Results The total effective rate of observation group and control group was 84.85%, 60.61% respectively, the difference was highly statistically significant (P < 0.01). The incidence of adverse reactions such as red blood cells decrease, thrombocytopenia, neutropenia, myelosuppression, skin reactions, radiation-induced oral mucositis, gastrointestinal reactions, electrocardiogram abnormalities, fever and others in the observation group was all significantly lower than those of control group, the differences were statistically significant (P < 0.05 or P < 0.01). The progression-free survival (PFS) of observation group was (6.4±0.4) months, and the median survival time (MST) was (14.6±1.8) months. For control group, the PFS was (4.2±0.6) months, and the MST was (11.1±1.5) months. The PFS and MST of observation group was obviously longer than those of control group (P < 0.01). Conclusion Nimotuzumab combined with Cisplatin concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma can improve clinical effects significantly, with few side effects and high safety, which is worthy of clinical application.
陈阳静 权 芳 王林古 李宏慧. 尼妥珠单抗联合顺铂同步放化疗治疗中晚期鼻咽癌的临床效果[J]. 中国医药导报, 2016, 13(3): 118-121.
CHEN Yangjing QUAN Fang WANG Lingu LI Honghui . Clinical effect of Nimotuzumab combined with Cisplatin concurrent che-moradiotherapy in the treatment of advanced nasopharyngeal carcinoma. 中国医药导报, 2016, 13(3): 118-121.